Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban vs Aspirin for Extended VTE Prevention
NCT02064439Phase 3Completed
- Sponsor
- Bayer
- Start
- Mar 2014
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 31
01
Overview
Phase 3, randomised, double-blind trial of rivaroxaban in venous thromboembolism (VTE) (3 arms), sponsored by Bayer. Primary endpoints: Composite of Fatal or Non-fatal Symptomatic Recurrent Venous Thromboembolism at 12 months and First Treatment-emergent Major Bleeding at 12 months. Started Mar 2014; status: completed.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT02064439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02064439.